Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group LY.12 -- A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation -- will officially close to further accrual to Randomization #2 (maintenance) as of 6:00 pm (EST) on Monday, December 31, 2012

Randomization #1 was closed in November 2011. All enrolled patients would now have completed salvage therapy and transplant required to be eligible for randomization #2 to maintenance therapy.

We would like to thank all participating centres, staff and patients for all of your efforts and participation in helping to bring this trial to a successful close.